Agreement of Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in the Company, the Company is pleased to confirm today that definitive agreements have now been signed for the Loan.

Further terms of the Loan and Related Party Transaction

The Company and David Nugent have entered into a Loan Agreement for up to £1.0 million in value (the "Loan"). The Loan is available to be drawn in two equal tranches of £500,000. The first tranche shall be requested imminently and shall not attract any commitment fee, interest or charges. The first tranche is expected to extend the Company's cash runway into February 2026. The second tranche will be available to be drawn down at the request and discretion of the Company on or after 20 February 2026 (or such other date as may be agreed between the Company and David Nugent). Draw down of the second tranche would incur a fixed fee of £50,000 which shall be added to the amount of principal and would need to be repaid upon repayment or conversion of the second tranche. The loan shall be secured by the grant of a debenture over all the Company's assets and is for a maximum period of twelve months. David Nugent currently intends that all amounts of the Loan drawn down shall be converted into equity as part of a future equity raise.

David Nugent is a related party of the Company pursuant to the AIM Rules and him being a party to the Loan constitutes a related party transaction for the purposes of AIM Rule 13. The Directors consider, having consulted with the Company's nominated adviser, Peel Hunt LLP, that the Company entering to the Loan with David Nugent is fair and reasonable insofar as Shareholders are concerned.

Dr Gino Miele, CEO of genedrive plc, said: "On behalf of the Company I extend my gratitude to David for providing this Loan on the terms now agreed. The Loan provides a valuable extension to our cash runway whist we continue to execute against our commercial and strategic goals and work towards longer term financing options."

Mr David Nugent, said: "I am delighted to provide this Loan to the Company as I am determined to ensure that the Company has the financial and other resources it needs to deliver for both patients and shareholders. As a significant shareholder in the Company I am also encouraged by the recent progress within genedrive which has coincided with a significant recovery in the Company's share price and I intend to provide further financial support to the Company going forwards."